Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

4
results for

"Sung Bum Cho"

Article category

Keywords

Publication year

"Sung Bum Cho"

Erratum

Erratum to ‘Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in directacting antiviral failure in South Korea’ [Clin Mol Hepatol 2023;29:496-509]
Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Seok Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong
Clin Mol Hepatol 2023;29(3):830-830.
Published online April 13, 2023
DOI: https://doi.org/10.3350/cmh.2022.0345e
Corrects: Clin Mol Hepatol 2023;29(2):496
  • 5,863 View
  • 33 Download
Original Articles

Viral hepatitis

Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea
Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Suk Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong
Clin Mol Hepatol 2023;29(2):496-509.
Published online March 6, 2023
DOI: https://doi.org/10.3350/cmh.2022.0345
Background/Aims
We used next-generation sequencing (NGS) to analyze resistance-associated substitutions (RASs) and retreatment outcomes in patients with chronic hepatitis C virus (HCV) infection who failed direct-acting antiviral agent (DAA) treatment in South Korea.
Methods
Using prospectively collected data from the Korean HCV cohort study, we recruited 36 patients who failed DAA treatment in 10 centers between 2007 and 2020; 29 blood samples were available from 24 patients. RASs were analyzed using NGS.
Results
RASs were analyzed for 13 patients with genotype 1b, 10 with genotype 2, and one with genotype 3a. The unsuccessful DAA regimens were daclatasvir+asunaprevir (n=11), sofosbuvir+ribavirin (n=9), ledipasvir/sofosbuvir (n=3), and glecaprevir/pibrentasvir (n=1). In the patients with genotype 1b, NS3, NS5A, and NS5B RASs were detected in eight, seven, and seven of 10 patients at baseline and in four, six, and two of six patients after DAA failure, respectively. Among the 10 patients with genotype 2, the only baseline RAS was NS3 Y56F, which was detected in one patient. NS5A F28C was detected after DAA failure in a patient with genotype 2 infection who was erroneously treated with daclatasvir+asunaprevir. After retreatment, 16 patients had a 100% sustained virological response rate.
Conclusions
NS3 and NS5A RASs were commonly present at baseline, and there was an increasing trend of NS5A RASs after failed DAA treatment in genotype 1b. However, RASs were rarely present in patients with genotype 2 who were treated with sofosbuvir+ribavirin. Despite baseline or treatment-emergent RASs, retreatment with pan-genotypic DAA was highly successful in Korea, so we encourage active retreatment after unsuccessful DAA treatment.

Citations

Citations to this article as recorded by  Crossref logo
  • Precision oncology through next generation sequencing in hepatocellular carcinoma
    Sayali Shinde, Carola Maria Bigogno, Ana Simmons, Nikita Kathuria, Aruni Ghose, Vedika Apte, Patricia Lapitan, Shania Makker, Aydin Caglayan, Stergios Boussios
    Heliyon.2025; 11(3): e42054.     CrossRef
  • Bridging the Gap in Elimination of Hepatitis C Virus among People Who Use Drugs in South Korea
    Beom Kyung Kim
    Gut and Liver.2025; 19(5): 635.     CrossRef
  • Correspondence on Letter regarding “Toward hepatitis C virus elimination using artificial intelligence”
    Ming-Ying Lu, Ming-Lung Yu
    Clinical and Molecular Hepatology.2024; 30(2): 274.     CrossRef
  • 9,537 View
  • 180 Download
  • 4 Web of Science
  • Crossref

Viral hepatitis

Geographic differences in the epidemiological features of HCV infection in Korea
Kyung-Ah Kim, Sook-Hyang Jeong, Eun Sun Jang, Young Seok Kim, Youn Jae Lee, Eun Uk Jung, In Hee Kim, Sung Bum Cho, Mee-Kyung Kee, Chun Kang
Clin Mol Hepatol 2014;20(4):361-367.
Published online December 24, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.4.361
Background/Aims

The prevalence of hepatitis C virus (HCV) infection in Korea exhibits significant geographic variation, with it being higher in Busan and Jeonam than in other areas. The reason for this intranational geographic difference was investigated in this study by conducting a comparative analysis of the risk factors related to HCV infection among three geographic areas: the capital (Seoul), Busan, and the province of Jeolla.

Methods

In total, 990 patients with chronic HCV infection were prospectively enrolled at 5 university hospitals located in Seoul (n=374), Busan (n=264), and Jeolla (n=352). A standardized questionnaire survey on the risk factors for HCV infection was administered to these three groups of patients, and a comparative analysis of the findings was performed.

Results

The analysis revealed significant regional differences in exposure to the risk factors of HCV infection. By comparison with patients in Seoul as a control group in the multivariate analysis, patients in Busan had significantly more experience of invasive medical procedures, acupuncture, cosmetic procedures, and multiple sex partners. In contrast, patients in Jeolla were significantly older, and they had a higher prevalence of hepatocellular carcinoma, a lower prevalence of multiple sex partners, and had experienced fewer invasive procedures.

Conclusions

There was a significant geographic difference in the exposure to potential risk factors of HCV infection between patients from the three studied regions. This may explain the regional variation of the prevalence of HCV infection in Korea, and should be taken into account when planning strategies for the prevention and management of HCV infection.

Citations

Citations to this article as recorded by  Crossref logo
  • 부산광역시, 울산광역시, 경상남도 지역의 C형간염 발생 현황 및 특성, 2018-2023년
    선태 김, 지은 엄, 혁진 이, 유진 조, 슬기 강, 동한 이, 상은 이
    Public Health Weekly Report.2025; 18(6): 277.     CrossRef
  • Epidemiology and Management of Hepatitis C in Korea
    Jaeyoun Cheong
    Korean Journal of Healthcare-Associated Infection Control and Prevention.2025; 30(2): 118.     CrossRef
  • 호남권 시도·시군구 단위의 C형간염 발생률 및 추이 분석, 2017-2021년
    영숙 최, 상용 엄, 정희 유
    Public Health Weekly Report.2023; 16(24): 743.     CrossRef
  • Epidemiology and treatment status of hepatitis C virus infection among people who have ever injected drugs in Korea: a prospective multicenter cohort study from 2007 to 2019 in comparison with non-PWID
    Kyung-Ah Kim, Gwang Hyun Choi, Eun Sun Jang, Young Seok Kim, Youn Jae Lee, In Hee Kim, Sung Bum Cho, Moran Ki, Hwa Young Choi, Dahye Paik, Sook-Hyang Jeong
    Epidemiology and Health.2021; 43: e2021077.     CrossRef
  • Prevalence, Awareness, and Treatment of Hepatitis C Virus Infection in South Korea: Evidence from the Korea National Health and Nutrition Examination Survey
    Kyung-Ah Kim, June Sung Lee
    Gut and Liver.2020; 14(5): 644.     CrossRef
  • Sofosbuvir plus ribavirin for the treatment of hepatitis C virus genotype 2 in Korea: What's the optimal dosage of ribavirin in real‐world setting?
    Jae Hyun Yoon, Chung Hwan Jun, Ji Ho Seo, Hyun A Cho, Sung Bum Cho, Sung Kyu Choi, Ju Yeon Cho, Man Woo Kim, Sung Wook Lim
    Journal of Digestive Diseases.2019; 20(1): 31.     CrossRef
  • A large healthcare-associated outbreak of hepatitis C virus genotype 1a in a clinic in Korea
    Yoon-Seok Chung, Ju-yeon Choi, Myung Guk Han, Kye Ryeong Park, Su-Jin Park, Hyerim Lee, Youngmee Jee, Chun Kang
    Journal of Clinical Virology.2018; 106: 53.     CrossRef
  • Seropositivity of Hepatitis C Virus among Persons affected Leprosy in Korea
    Jong-Pill Kim, Kuk-Hyeong Kang, Jin-Mo Park
    Korean Leprosy Bulletin.2018; 51(1): 13.     CrossRef
  • KASL clinical practice guidelines: management of hepatitis C

    Clinical and Molecular Hepatology.2016; 22(1): 76.     CrossRef
  • Recent outbreaks of hepatitis C virus infection in Korea and strategy for prevention
    In Hee Kim
    Journal of the Korean Medical Association.2016; 59(12): 912.     CrossRef
  • Recent outbreaks of hepatitis C virus infection in Korea and strategy for prevention
    In Hee Kim
    Journal of the Korean Medical Association.2016; 59(12): 912.     CrossRef
  • Clinical Characteristics of Defectors from North Korea Visiting a Single Tertiary Hospital in South Korea
    Sun Young Ann, Sung Hyeok Ryou, Suk Bae Kim
    Korean Journal of Medicine.2015; 89(1): 54.     CrossRef
  • Epidemiology of Hepatitis C Virus Infection in Korea
    Sook-Hyang Jeong
    Korean Journal of Medicine.2015; 88(6): 630.     CrossRef
  • 10,983 View
  • 64 Download
  • 6 Web of Science
  • Crossref

Hepatic neoplasm

Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE
Chung Hwan Jun, Ho Seok Ki, Ki Hoon Lee, Kang Jin Park, Seon Young Park, Sung Bum Cho, Chang Hwan Park, Young Eun Joo, Hyun Soo Kim, Sung Kyu Choi, Jong Sun Rew
Korean J Hepatol 2013;19(1):70-77.
Published online March 25, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.1.70
Background/Aims

The aim of this study was to determine the relationship between serum CRP levels and the prognosis of hepatocellular carcinoma (HCC) patients.

Methods

HCC patients who underwent the first session of transcatheter arterial chemoembolization (TACE) between January 2005 and December 2009 (n=211) were analyzed retrospectively. The patients were divided into two groups: high C-reactive protein (CRP; ≥1 mg/dL, n=51) and low CRP (<1 mg/dL, n=160). They were followed for a mean of 22.44 months and their clinicoradiological variables and overall survival were compared.

Results

There were significant differences between the two groups in regard to tumor type, tumor-progression-free survival, 10-month mortality, white blood cell (WBC) count, tumor size, and TNM stage. Multivariate analysis revealed that a high serum CRP level was independently associated with tumor size and tumor type. Subgroup analysis of CRP groups according to tumor size demonstrated that a high serum level of CRP was significantly associated with poorly defined (diffuse) tumor type in the tumor size <5 cm group [hazard ratio (HR)=4.81, P=0.018]. A Lipiodol dose exceeding 7 mL (HR=5.55, P=0.046) and the 10-month mortality (HR=7.693, P=0.004) were significantly associated with high serum CRP level in the group of patients with a tumor size of ≥5 cm. In addition, subgroup analysis of matched CRP according to TNM stage revealed that elevated serum CRP was independently associated with tumor type, WBC count, and tumorprogression-free survival.

Conclusions

A high serum CRP level is associated with large tumors and a poorly defined tumor type, and is significantly associated with 10-month mortality in patients with large HCC (size ≥5 cm) who undergo TACE.

Citations

Citations to this article as recorded by  Crossref logo
  • Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma
    Young Mi Hong
    European Journal of Gastroenterology & Hepatology.2025; 37(1): 94.     CrossRef
  • Nurses' comfort care of transarterial chemoembolization patients based on their perceptions around postembolization syndrome and symptom interference
    Myoung Soo Kim, Minkyeong Kang, Jiwon Park, Jung Mi Ryu
    Nursing Open.2023; 10(5): 2877.     CrossRef
  • Prognostic value of preoperative prealbumin levels in patients with unresectable hepatocellular carcinoma undergoing transcatheter arterial chemoembolisation
    Kai Lei, Jia-Guo Wang, Yin Li, Hong-Xiang Wang, Jie Xu, Ke You, Zuo-Jin Liu
    Heliyon.2023; 9(8): e18494.     CrossRef
  • Prognostic implications of alpha-fetoprotein and C-reactive protein elevation in hepatocellular carcinoma following resection (PACE): a large cohort study of 2770 patients
    Kong-Ying Lin, Qing-Jing Chen, Shi-Chuan Tang, Zhi-Wen Lin, Jian-Xi Zhang, Si-Ming Zheng, Yun-Tong Li, Xian-Ming Wang, Qiang Lu, Jun Fu, Luo-Bin Guo, Li-Fang Zheng, Peng-Hui You, Meng-Meng Wu, Ke-Can Lin, Wei-Ping Zhou, Tian Yang, Yong-Yi Zeng
    BMC Cancer.2023;[Epub]     CrossRef
  • Risk Predictors of Post-Embolization Syndrome after Transarterial Chemoembolization by Sex: A Retrospective Study
    Han Byeol Lim, Myoung Soo Kim
    Korean Journal of Adult Nursing.2023; 35(4): 418.     CrossRef
  • Transient deterioration of albumin–bilirubin scores in early post-dose period of molecular targeted therapies in advanced hepatocellular carcinoma with 50% or higher liver occupation
    Hisanori Muto, Teiji Kuzuya, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Masatoshi Ishigami, Mitsuhiro Fujishiro
    Medicine.2021; 100(31): e26820.     CrossRef
  • Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide
    Lukas Müller, Fabian Stoehr, Aline Mähringer-Kunz, Felix Hahn, Arndt Weinmann, Roman Kloeckner
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 403.     CrossRef
  • Genetic and biochemical studies of hepatic carcinoma in the Egyptian population
    Amany F Elkhoudary, Rehab Elmougy, Afaf Elsaid, Yahya Wahba, Abdel-Aziz F Abdel-Aziz
    Journal of Research in Medical Sciences.2021; 26(1): 62.     CrossRef
  • Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
    Young Eun Chon, Hana Park, Hye Kyung Hyun, Yeonjung Ha, Mi Na Kim, Beom Kyung Kim, Joo Ho Lee, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Seong Gyu Hwang, Kwang-Hyub Han, Kyu Sung Rim, Jun Yong Park
    Cancers.2019; 11(4): 509.     CrossRef
  • Clinical and prognostic implications of pretreatment albumin to C-reactive protein ratio in patients with hepatocellular carcinoma
    Mian-Tao Wu, Su-Yin He, Shu-Lin Chen, Lin-Fang Li, Zheng-Qiang He, Yuan-Ying Zhu, Xia He, Hao Chen
    BMC Cancer.2019;[Epub]     CrossRef
  • Significance of the Glasgow Prognostic Score in Predicting the Postoperative Outcome of Patients with Stage III Gastric Cancer
    Shun-Wen Hsueh, Keng-Hao Liu, Chia-Yen Hung, Yung-Chia Kuo, Chun-Yi Tsai, Jun-Te Hsu, Yu-Shin Hung, Ngan-Ming Tsang, Wen-Chi Chou
    Journal of Clinical Medicine.2019; 8(9): 1448.     CrossRef
  • Is there an association between CRP levels and tumor size in breast cancer patients?
    Emine Petekkaya, Ibrahim Petekkaya, Erdinc Nayır, Kadrid Altundağ
    Journal of Oncological Sciences.2018; 4(2): 106.     CrossRef
  • Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma
    Aline Mähringer-Kunz, Roman Kloeckner, Michael B. Pitton, Christoph Düber, Irene Schmidtmann, Peter R. Galle, Sandra Koch, Arndt Weinmann
    CardioVascular and Interventional Radiology.2017; 40(7): 1017.     CrossRef
  • Prognostic value of the combination of serum levels of vascular endothelial growth factor, C-reactive protein and contrast-enhanced ultrasound in patients with primary liver cancer who underwent transcatheter arterial chemoembolization
    Zhi-Dong Xuan, Li Zhou, Yu Wang, Xue Zheng
    Expert Review of Anticancer Therapy.2017; 17(12): 1169.     CrossRef
  • Postoperative peak serum C-reactive protein is a predictor of outcome following liver transplantation for hepatocellular carcinoma
    Arno Kornberg, Ulrike Witt, Jennifer Kornberg, Katharina Müller, Helmut Friess, Katharina Thrum
    Biomarkers.2016; 21(2): 152.     CrossRef
  • The CRP level and STATE score predict survival in cirrhotic patients with hepatocellular carcinoma treated by transarterial embolization
    Samia Rekik, Erwan Guyot, Mohannad Bhais, Yves Ajavon, Véronique Grando, Valérie Bourcier, Gisèle Nkontchou, Pierre Nahon, Nicolas Sellier, Olivier Seror, Nathalie Ganne-Carrie, Jean-Charles Nault
    Digestive and Liver Disease.2016; 48(9): 1088.     CrossRef
  • Use of18F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization
    Min Jin Kim, Young Seok Kim, Youn Hee Cho, Hee Yoon Jang, Jeong-Yeop Song, Sae Hwan Lee, Soung Won Jeong, Sang Gyune Kim, Jae Young Jang, Hong Su Kim, Boo Sung Kim, Won Hyung Lee, Jung Mi Park, Jae Myung Lee, Min Hee Lee, Deuk Lin Choi
    The Korean Journal of Internal Medicine.2015; 30(3): 308.     CrossRef
  • Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors
    Jeong-Yeop Song, Yun Nah Lee, Young Seok Kim, Sang Gyune Kim, Soo Ji Jin, Jung Mi Park, Gyu Seong Choi, Jun Chul Chung, Min Hee Lee, Youn Hee Cho, Moon Han Choi, Dong Choon Kim, Hyun Jong Choi, Jong Ho Moon, Se Hwan Lee, Seung Won Jeong, Jae Young Jang, H
    Nuclear Medicine Communications.2015; 36(4): 319.     CrossRef
  • Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome
    A. Kornberg
    ISRN Hepatology.2014; 2014: 1.     CrossRef
  • 12,300 View
  • 79 Download
  • 26 Web of Science
  • Crossref